Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Publication | Closed Access

DOI

304

Citations

References

2015

Year

Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva, Giovanni DiPerri, Jan van Lunzen, Ellen Koenig, Richard Elion, Matthias Cavassini, Jose Valdez Madruga, Jason Brunetta,

The Lancet Infectious Diseases

Hiv/aids CounsellingTreatment And PreventionPharmacologyClinical TrialsAntiviral Drug DevelopmentAntiviral TherapyNon-inferiority StudyPharmacotherapyChronic Viral InfectionAntiviral DrugHivMedicineTenofovir Disoproxil FumaratePhase 3